477 related articles for article (PubMed ID: 23435813)
21. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
[TBL] [Abstract][Full Text] [Related]
22. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
23. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.
Gianotti N; Soria A; Galli L; Castagna A; Cernuschi M; Hasson H; Lazzarin A
J Med Virol; 2004 Feb; 72(2):181-6. PubMed ID: 14695657
[TBL] [Abstract][Full Text] [Related]
24. Successful application of laboratory tools for the detection of HIV drug resistance in routine clinical care in Georgia.
Chkhartishvili N; Dvali N; Gochitashvili N; Sharvadze L; Tsertsvadze T
Georgian Med News; 2008 Dec; (165):16-22. PubMed ID: 19124911
[TBL] [Abstract][Full Text] [Related]
25. [Drug resistance in antiretroviral therapy of HIV infection].
Oette M; Häussinger D
Med Klin (Munich); 2003 Dec; 98(12):692-9. PubMed ID: 14685670
[TBL] [Abstract][Full Text] [Related]
26. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
Frange P; Briand N; Avettand-fenoel V; Veber F; Moshous D; Mahlaoui N; Rouzioux C; Blanche S; Chaix ML
Pediatr Infect Dis J; 2011 Aug; 30(8):684-8. PubMed ID: 21427626
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.
Imaz A; Llibre JM; Mora M; Mateo G; Camacho A; Blanco JR; Curran A; Santos JR; Caballero E; Bravo I; Gayá F; Domingo P; Rivero A; Falcó V; Clotet B; Ribera E
J Antimicrob Chemother; 2011 Feb; 66(2):358-62. PubMed ID: 21172789
[TBL] [Abstract][Full Text] [Related]
28. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
29. Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar years: a cohort study.
Bracciale L; Fanti I; Di Giambenedetto S; Colafigli M; Prosperi M; Bacarelli A; Santangelo R; Cattani P; Cauda R; De Luca A
J Clin Virol; 2009 Nov; 46(3):290-4. PubMed ID: 19699675
[TBL] [Abstract][Full Text] [Related]
30. Current concepts in antiretroviral therapy failure.
del Rio C
Top HIV Med; 2006; 14(3):102-6. PubMed ID: 16946454
[TBL] [Abstract][Full Text] [Related]
31. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.
Saracino A; Gianotti N; Marangi M; Cibelli DC; Galli A; Punzi G; Monno L; Lazzarin A; Angarano G;
J Med Virol; 2008 Oct; 80(10):1695-706. PubMed ID: 18712823
[TBL] [Abstract][Full Text] [Related]
32. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
[TBL] [Abstract][Full Text] [Related]
33. Salvage therapies get attention at conference.
Rodriguez E
Posit Living; 1999 Nov; 8(10):6, 45, 47. PubMed ID: 11367335
[TBL] [Abstract][Full Text] [Related]
34. HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.
Wilson LE; Gallant JE
Clin Infect Dis; 2009 Jan; 48(2):214-21. PubMed ID: 19072245
[TBL] [Abstract][Full Text] [Related]
35. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
[TBL] [Abstract][Full Text] [Related]
36. Preventing and managing antiretroviral drug resistance.
Kuritzkes DR
AIDS Patient Care STDS; 2004 May; 18(5):259-73. PubMed ID: 15186710
[TBL] [Abstract][Full Text] [Related]
37. Antiretroviral therapy: treatment-experienced individuals.
Calvo KR; Daar ES
Infect Dis Clin North Am; 2014 Sep; 28(3):439-56. PubMed ID: 25151565
[TBL] [Abstract][Full Text] [Related]
38. Treatment of antiretroviral-drug-resistant HIV-1 infection.
Deeks SG
Lancet; 2003 Dec; 362(9400):2002-11. PubMed ID: 14683662
[TBL] [Abstract][Full Text] [Related]
39. The road to success. Long-term prognosis for persons living with HIV in Denmark - time trends and risk factors.
Lohse N
Dan Med J; 2016 Feb; 63(2):. PubMed ID: 26836803
[TBL] [Abstract][Full Text] [Related]
40. Antiretroviral therapy for HIV: drug resistance and sequencing.
Burkle WS
J Assoc Nurses AIDS Care; 2002; 13(1):76-80. PubMed ID: 11828862
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]